Alnylam Pharmaceuticals, Inc. (ALNY): Rasio rega marang dodolan

Logo korporat perusahaan Alnylam Inc. (ALNY)

Alnylam Pharmaceuticals relies on inelastic demand driven by its unique therapies for rare pathologies. The company's normalized P/S on GURU.Markets reflects market expectations, where 4.40 represents the current metric level. Professional management ensures transparency in the development of RNA interference and strives for full self-sufficiency. Modern biotechnological capacities are operating stably while undergoing scheduled line modernizations.

ALNY: Multiplikator P/S Alnylam Pharmaceuticals 04.07.2022 - 15.11.2026

Rincian metrik lan analitis perusahaan alnylam.com (ALNY)

Analisis umum perusahaan:ALNY Alnylam
Produk dadi Alnylam Pharmaceuticals

The P/S ratio relates a business's market capitalization to its annual revenue, allowing an investor to determine the premium paid per unit of sales. The current value of 4.40, represented by the price-to-sales ratio, reflects the premium for Alnylam Pharmaceuticals (ALNY) patent monopoly in the field of RNA interference, confirming the fundamental stability of the company's high margins and leadership in the rare disease market.

Perusahaan pesaing

VRTX (Vertex Pharmaceuticals Incorporated) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Insmed INSM|UTHR (United Therapeutics Corp.) - Rasio rega marang dodolan|BioMarin Pharmaceutical - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan BBIO (BridgeBio Pharma, Inc.)|BGM Group Corp (BGM) - Rasio rega marang pendapatan|Cogent Biosciences Inc (COGT) - Multiplikator P/S|Rasio rega marang pendapatan Xeris Biopharma Inc|KROS: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan arcturusrx.com (ARCT)|Kapitalisasi marang pendapatan Eton Pharmaceuticals ETON|Multiplikator P/S KMDA (kamada.com)|Multiplikator P/S Fulcrum Therapeutics, Inc. FULC|Abeona Therapeutics - Multiplikator P/S|mereobiopharma.com (MREO) - Kapitalisasi marang pendapatan|Protalix BioTherapeutics Inc. (PLX) - Rasio rega marang pendapatan|PLRX (Pliant Therapeutics Inc) - Rasio rega marang pendapatan|Rasio rega marang pendapatan Applied Therapeutics, Inc.|Rein Therapeutics Inc. (RNTX) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan GELS (Gelteq Limited)|Multiplikator P/S Aytu Therapeutics (AYTU)|Rasio rega marang pendapatan Chemomab Therapeutics Ltd. CMMB|Rasio kapitalisasi pasar marang pendapatan SRXH|Polyrizon Limited - Multiplikator P/S|AEZS (zentaris.com) - Rasio kapitalisasi marang pendapatan|CYTH (Cyclo Therapeutics, Inc.) - Kapitalisasi marang pendapatan|Rega marang dodolan Inozyme Pharma, Inc. (INZY)|RPHM (Reneo Pharmaceuticals) - Multiplikator P/S|COSCIENS Biopharma (CSCI) - Koefisien rega marang pendapatan